ANCA associated vasculitis in China

Size: px
Start display at page:

Download "ANCA associated vasculitis in China"

Transcription

1 ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing , P. R. China 1

2 General introduction of AAV in China Disease spectrum and ANCA type Clinical and pathological study Treatment and outcomes Pathogenic studies Complement and neutrophils 2

3 General introduction of AAV in China Disease spectrum and ANCA type Clinical and pathological study Treatment and outcomes Pathogenic studies Complement and neutrophils 3

4 2012 Chapel Hill Consensus Conference Vasculitis Nomenclature Large Vessel Vasculitis Giant Cell Arteritis Takayasu Arteritis Medium Vessel Vasculitis Polyarteritis Nodosa Kawasaki Disease Small Vessel Vasculitis ANCA Associated Vasculitis Microscopic Polyangiitis Granulomatosis with Polyangiitis (Wegener s) Eosinophilic Granulomatosis with Polyangiitis (Churg Strauss) Immune Complex Vasculitis Anti GBM Disease IgA Vasculitis (Henoch Schönlein) Cryoglobulinemic Vasculitis Hypocomplementemic Urticarial Vasculitis (Anti C1q Vasculitis) Variable Vessel Vasculitis (Cogan s, Behcet s, etc.) Single Organ Vasculitis (cutaneous SVV, primary CNS vasculitis, etc.) Vasculitis Associated with Systemic Diseases (e.g. Rheumatoid, Lupus, Sarcoid, etc.) Vasculitis Associated with Probable Etiologies (e.g. HBV, HCV, drug, cancer, etc.) 4

5 ANCA vasculitis in China A common autoimmune disease in Western countries No epidemiological data available in China yet End of 1980s Began to diagnose a few patients End of 1990s Established methods for ANCA test The number of patients increased rapidly 2000s Start to establish our cohort More than 500 patients with long term regular follow up Nearly 300 patients with renal biopsy sample Biobank: blood, urine, renal biopsy, DNA In our center 5

6 Disease spectrum A striking preponderance of MPA: 60 80% of the patients % * * P<0.01, # P<0.001 with AAV In older patients, the proportion of MPA is even higher than youngers * # Chen M, et al. Postgrad Med J 2005; 81:723 7 Chen M, et al. Medicine (Baltimore) 2009; 87:

7 GPA: MPO ANCA (+) vs. PR3 ANCA(+) 100% 75% 61,8% 81,5% 55,8% 100% 75% 81.5% 61.8% 42.6% 70.6% 50% 27,8% 50% 25% 25% 0% eye ear 0% initial Scr male MPO -ANCA PR3-ANCA MPO-ANCA PR3-ANCA Compare with traditional PR3 ANCA(+) GPA, MPO ANCA(+) GPA was: female predominant less common on head and neck involvement More chronic lesion in renal histology? Chen M, et al. Kidney Int 2005 Chen M, et al. Nephrol Dial Transplant

8 General introduction of AAV in China Disease spectrum and ANCA type Clinical and pathological study Treatment and outcomes Pathogenic studies Complement and neutrophils 8

9 Induction therapy Treatment Corticosteroids plus CTX /Rituximab Plasma exchange for severe ones Maintenance therapy AZA MMF Dose of immunosuppressant is less than Caucasians 9

10 Outcomes Mortality Relapse and treatment resistance Renal outcomes 10

11 Predictors of various outcomes in AAV A large cohort of 500+ pts., follow up more about 15 yr endpoint mortality predictors Age, Scr, infection relapse Pulmonary, Scr ESRD Normal G, T I lesion Lai QY, et al. J Rheumatol 2014 Chen M, et al. Medicine (Baltimore) 2008; 87: Li ZY, et al. Arthritis Rheumatol 2014; 66: Li ZY, et al. Semin Arthritis Rheum

12 Mortality Study from EUVAS: early mortality is a crucial issue Active vasculitis per se Complication from heavy burden of immunosuppressive therapy: esp. infection Ann Rheum Dis 2009

13 Mortality 398 patients, with a median follow up of 25.5 (range 1 196) months, with 83/135 death happening within the first year Lai QY, et al. J Rheumatol 2014 Chen M, et al. Medicine (Baltimore) 2008; 87:

14 Predictors of all cause mortality: older age (p<0.001), secondary infection (p<0.001) initial Scr (p<0.001) Leading cause of death Within 1 year: secondary infection (53/153, 39.3%) After 1 year: cardiovascular events (15/53, 28.8%) Predictors of secondary infection lymphocyte counts in the peripheral blood (p=0.004) basic pulmonary involvement of AAV (p<0.001) older age Lai QY, et al. J Rheumatol 2014 Chen M, et al. Medicine (Baltimore) 2008; 87:

15 Shi YY, et al. Medicine

16 Cardiovascular outcomes 504 patients,median follow up 38 (1 228) months CV events:117, CV mortality: 41

17

18 Treatment resistance and relapse Relapse is an independent predictor of ESRD Study from North Carolina and France Predictors of relapse PR3-ANCA Upper respiratory tract and lung involvement Lung involvement Predictors of treatment resistance Older age Female African American MPO-ANCA Poor renal function Hogan SL, et al. Ann Intern Med. 2005;143: Pagnoux C, et al.. Arthritis Rheum. 2008;58:

19 Treatment resistance and relapse Our center: 439 AAV patients Treatment resistance: 47/439 (10.7%) higher Scr (OR 1.087, 95%CI , P=0.047) ESR level (OR 1.009, 95%CI , P=0.025) Relapse: 128/392 in 48 (range 3 171) months lung involvement (HR 1.768, 95%CI , P=0.021) lower Scr (HR 0.925, 95%CI , P=0.009) Li ZY, et al. Arthritis Rheumatol 2014; 66:

20 Predictors for renal restoration in severe ANCA GN 89 ANCA GN patients on dialysis at presentation At the 6th month of treatment, 28.1% dialysis independent, 50.6% ESRD, 21.3% died, including 9/19 died from infection Predictor of renal restoration Proportion of normal G Extent of tubular atrophy and intersititial fibrosis Leading cause of death: infection Li ZY, et al. Semin Arthritis Rheum

21 Prospective How to control active AAV How to avoid infection Cardiovascular disease Malignancy Quality of life/mental health Biomarkers to predict disease severity/outcomes 21

22 General introduction of AAV in China Disease spectrum and ANCA type Clinical and pathological study Treatment and outcomes Pathogenic studies Complement activation 22

23 PNAS 1990

24 Pauci immune No hypocomplementemia Complement did not play a key role Ag Ab reaction complement activation C3c deposition, more severe disease Complement activation C3c: 37/112 (33.0%), severe renal lesion Heavy proteinuria Poor renal function More crescent Severe TI injury Chen M et al. Nephrol Dial Transplant 2009;48(4):

25 Renal histology: Bb~ crescent, Bb~ TI lesion Urine Bb~ Scr Bb~ normal G Gou SJ, et al. Clin J Am Soc Nephrol

26 Complement activation in circulation: AP Bb in circulation ~ disease activity Gou SJ, et al. Kidney Int 2013

27 Factor H:negative regulator of AP Chen SF, et al. Arthritis Res Ther 2015

28 MPO released from ANCA activated neutrophil binds mcrp Such binding may block the binding of mcrp FH, thus inhibit the regulatory effect of FH on AP Xu PC, et al. Innate Immunity 2014

29 The complement regulatory activity of FH was deficient in AAV AP in AAV Overactivation Dysregulation Chen SF, et al. Clin Immunol

30 Huugen D, et al. Kidney Int 2007; 71: Schreiber A, et al. J Am soc Nephrol 2009; 20: Xiao H, et al. J Am soc Nephrol 2014; 25:

31 Pathogenic role of C5a Arthritis Rheumatol 2015 Kidney Int

32 Neutrophil extracellular traps,nets AP neutrophils Wang H, et al. Clin Exp Immunol

33 Priming TNF-α C5a Priming ANCA C5 C5b (C3b)nBbP C5 convertase C3 C3bBbP C3 convertase C3b(H 2 O)BbP +C3b C3b C3a C3bB p D C3 B P Wang H, et al. Clin Exp Immunol 2015

34 C5aR/CD88 small molecule antagonist CCX168 in AAV: The CLEAR trial (1) prednisone 60mg/day, (2) CCX mg b.i.d.+ prednisone 20 mg + CTX or RTX (3) CCX mg b.i.d. CCX168 successfully replaced glucocorticoid treatment, with a more rapid onset of action based on BVAS, UACR, HRQOL, a lower incidence of steroid-related adverse effects. Jayne D et al. J Am Soc Nephrol 2017

35 Two players: ANCA, neutrophils

36 Three players: ANCA, neutrophils, complement

37 Take home message AAV is a group of common autoimmune disease in China, MPO AAV is the most common type Pred + CTX is the mainstay of treatment, secondary infection the main cause of death nowadays. Complement activation is a crucial aspect in the pathogenesis and treatment target

38 38

EUVAS update June 5 th Marinka Twilt

EUVAS update June 5 th Marinka Twilt EUVAS update June 5 th 2012 Marinka Twilt Chapel Hill 2012 Classification Large Vessel Vasculitis (LVV) Medium Vessel Vasculitis (MVV) Small Vessel Vasculitis (SVV) Variable Vessel Vasculitis (VVV) Single

More information

SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018

SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018 SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018 OUTLINE Renal involvement in vasculitis Curr Rheumatol Rep 2013 Renal involvement in ANCA vasculitis GN***:

More information

Plasma exchanges in ANCA-associated vasculitis

Plasma exchanges in ANCA-associated vasculitis Plasma exchanges in ANCA-associated vasculitis Xavier Puéchal, MD, PhD Centre de Référence des Maladies auto-immunes systémiques rares d Ile de France Hôpital Cochin Université Paris Descartes http://www.vascularites.org

More information

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Annual Rheumatology & Therapeutics Review for Organizations & Societies Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with

More information

Vascularites rénales associées aux ANCA

Vascularites rénales associées aux ANCA Vascularites rénales associées aux ANCA Société Médicale des Hôpitaux de Paris 16 Mars 2012 Philippe Vanhille Néphrologie et Médecine Interne Hôpital de Valenciennes Classification of systemic vasculitis:

More information

ANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic

ANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic ANCA-associated vasculitis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas,

More information

Small Vessel Vasculitis

Small Vessel Vasculitis Small Vessel Vasculitis Paul A Brogan Professor of Vasculitis and Consultant Paediatric Rheumatologist Department of Rheumatology Institute of Child Health and Great Ormond St Hospital, London UK P.brogan@ucl.ac.uk

More information

Mohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward

Mohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward VASCULITIS SYNDROMES Mohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward ILLUSTRATED CASE 1 A 56 years old lady refered me for prolonged fever, arthritis

More information

Small Vessel Vasculitis

Small Vessel Vasculitis Banff- Rocky Mountain Barry Kassen, MD, FRCPC,FACP Head, Division of Internal Medicine UBC/VGH/SPH Acting Head, Division of Community Internal Medicine November, 2009 Objectives 1. To understand small

More information

Vasculitis. Edward Dwyer, M.D. Division of Rheumatology. Vasculitis

Vasculitis. Edward Dwyer, M.D. Division of Rheumatology. Vasculitis Edward Dwyer, M.D. Division of Rheumatology VASCULITIS is a primary inflammatory disease process of the vasculature Determinants of the Clinical Manifestations of : Target organ involved Size of vessel

More information

Recent advances in management of Pulmonary Vasculitis. Dr Nita MB

Recent advances in management of Pulmonary Vasculitis. Dr Nita MB Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction

More information

Tell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital

Tell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA

More information

Diagnostic Procedures for Vasculitis

Diagnostic Procedures for Vasculitis Diagnostic Procedures for Vasculitis Toshiharu Matsumoto, MD Clinical Professor of Department of Diagnostic Pathology Juntendo University Nerima Hospital, Tokyo, Japan Introduction In 1994, the International

More information

GRANULOMATOSIS WITH POLYANGIITIS

GRANULOMATOSIS WITH POLYANGIITIS What is granulomatosis with polyangiitis (GPA)? Granulomatosis with polyangiitis (GPA) is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict

More information

New Developments in ANCA-associated Vasculitis

New Developments in ANCA-associated Vasculitis New Developments in ANCA-associated Vasculitis Second International Renal Conference Bruges, March 2018 Ulrich Specks, M.D. Connor Group Foundation Professor of Medicine Mayo Clinic College of Medicine

More information

Management of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe

Management of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe Management of Acute Vasculitis CMT teaching 3 rd June 2015 Caroline Wroe Vasculitis pub quiz Match the date with the event Dr Peter McBride, Scottish Otolaryngologist describes a disease of rapid destruction

More information

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Vasculitis Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Disease Spectrum Hypersensitivity vasculitis/microscopic

More information

ANCA+ VASCULITIDES CYCAZAREM,

ANCA+ VASCULITIDES CYCAZAREM, ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed

More information

Updates from the 15 th ANCA workshop

Updates from the 15 th ANCA workshop Updates from the 15 th ANCA workshop Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France Nataliya Milman, MD Ottawa, Canada Simon Carette, MD, MPhil, FRCP

More information

TREATMENT OF ANCA-ASSOCIATED VASCULITIS

TREATMENT OF ANCA-ASSOCIATED VASCULITIS TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,

More information

SHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth

SHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth SHO Teaching Vasculitis Renal medicine Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth OUTLINE What is vasculitis Causes Classification Brief look into ANCA Associated Vasculitis (AAV)

More information

PAEDIATRIC VASCULITIS

PAEDIATRIC VASCULITIS PAEDIATRIC VASCULITIS Lawrence Owino Okong o, Mmed (UoN); Mphil. (UCT). Lecturer, Department of Paediatrics and Child Health, University of Nairobi. Paediatrician/ Rheumatologist. OUTLINE Introduction

More information

New biomarkers for ANCA-associated Vasculitis? Juliana Bordignon Draibe

New biomarkers for ANCA-associated Vasculitis? Juliana Bordignon Draibe New biomarkers for ANCA-associated Vasculitis? Juliana Bordignon Draibe Summary Introduction Antibodies: ANCAs, Anti-LAMP-2, Anti-moesin B and T lymphocytes Markers of vascular activation: complement,

More information

Complement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna

Complement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna Complement in vasculitis and glomerulonephritis Andy Rees Clinical Institute of Pathology Medical University of Vienna 41 st Heidelberg Nephrology Seminar March 2017 The complement system An evolutionary

More information

Atypical IgA Nephropathy

Atypical IgA Nephropathy Atypical IgA Nephropathy Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA XXXIII Chilean Congress of Nephrology, Hypertension and Transplantation Puerto Varas, Chile October 6, 2016 IgA

More information

Managing Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge

Managing Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge Managing Acute Medical Problems, Birmingham 2016 Vasculitis David Jayne University of Cambridge Disclosures Astra Zeneca, Aurinia, BIOGEN, Boehringer, Chemocentryx, Genzyme/Sanofi, GSK, Lilly, Medimmune,

More information

VASCULITIC SYNDROMES. Howard L. Feinberg, D.O., F.A.C.O.I., F.A.C.R. OPSC 2018

VASCULITIC SYNDROMES. Howard L. Feinberg, D.O., F.A.C.O.I., F.A.C.R. OPSC 2018 VASCULITIC SYNDROMES Howard L. Feinberg, D.O., F.A.C.O.I., F.A.C.R. OPSC 2018 2012 REVISED CHAPEL HILL CONSENSUS CONFERENCE Large vessel Takayasu arteritis Giant cell arteritis Medium Vessel Polyarteritis

More information

AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS

AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS GRANULOMATOSIS WITH POLYANGIITIS (GPA), MICROSCOPIC POLYANGIITIS (MPA), and EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS What is ANCA-associated Vasculitis?

More information

Vasculitis and Vasculitides. OMONDI OYOO Physician/Rheumatologist; Senior Lecturer, Department of Medicine University of Nairobi

Vasculitis and Vasculitides. OMONDI OYOO Physician/Rheumatologist; Senior Lecturer, Department of Medicine University of Nairobi Vasculitis and Vasculitides OMONDI OYOO Physician/Rheumatologist; Senior Lecturer, Department of Medicine University of Nairobi Definition Presence of leucocytes in the vessel wall with reactive damage

More information

Year In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis

Year In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis Year In Review: VasculitisPers Cailin Sibley, M.D., M.H.S. Director, Vasculitis Clinic April 27 th, 2018 NTEREST DISCLOSURE Disclosures none Learning Objectives Describe new medications for the treatment

More information

A number of factors point to the likelihood of a person with RA developing RV:

A number of factors point to the likelihood of a person with RA developing RV: What is rheumatoid vasculitis (RV)? Rheumatoid vasculitis (RV) is a rare but serious complication of rheumatoid arthritis (RA) an inflammatory disease that causes severe joint pain and damage, and can

More information

CENTRAL NERVOUS SYSTEM VASCULITIS

CENTRAL NERVOUS SYSTEM VASCULITIS What is central nervous system (CNS) vasculitis? Central nervous system (CNS) vasculitis is among a family of rare disorders characterized by inflammation of the blood vessels, which restricts blood flow

More information

Vasculitis Update. A selective review of what s new. Dr Jonathan Akikusa MBBS FRACP

Vasculitis Update. A selective review of what s new. Dr Jonathan Akikusa MBBS FRACP Vasculitis Update A selective review of what s new Dr Jonathan Akikusa MBBS FRACP Consultant Paediatric Rheumatologist Royal Children s Hospital, Melbourne Honorary Research Fellow Murdoch Children s Research

More information

RATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with

RATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with http://www.kidney-international.org chapter 13 & 2012 KDIGO Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis Kidney International Supplements (2012) 2, 233 239; doi:10.1038/kisup.2012.26

More information

Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease

Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease Article Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease JulieAnne G. McGregor, Susan L. Hogan, Yichun Hu, Caroline E. Jennette, Ronald J. Falk, and Patrick

More information

Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study

Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study Manno et al. BMC Nephrology (2015) 16:88 DOI 10.1186/s12882-015-0082-9 RESEARCH ARTICLE Open Access Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective

More information

Chapter 2 Animal Models of ANCA-Associated Vasculitides

Chapter 2 Animal Models of ANCA-Associated Vasculitides Chapter 2 Animal Models of ANCA-Associated Vasculitides Domenico Ribatti and Franco Dammacco Abstract Antibodies against neutrophil proteins myeloperoxidase (MPO) and proteinase- 3 (PR3) are responsible

More information

GIANT CELL ARTERITIS. Page 1 of 6 Reproduction of this material requires written permission of the Vasculitis Foundation. Copyright 2018.

GIANT CELL ARTERITIS. Page 1 of 6 Reproduction of this material requires written permission of the Vasculitis Foundation. Copyright 2018. What is giant cell arteritis (GCA)? Giant cell arteritis (GCA) is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage

More information

ENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. J. María Pego Reigosa

ENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. J. María Pego Reigosa ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. J. María Pego Reigosa ABSTRACT NUMBER: 888 PHASE 3 TRIAL RESULTS WITH BLISIBIMOD, A SELECTIVE INHIBITOR OF B-CELL ACTIVATING FACTOR, IN SUBJECTS WITH MODERATE-TO-SEVERE

More information

Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody associated vasculitis

Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody associated vasculitis http://www.kidney-international.org & 212 International Society of Nephrology see commentary on page 16 Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody associated

More information

Rituximab treatment for ANCA-associated vasculitis in childhood

Rituximab treatment for ANCA-associated vasculitis in childhood Rituximab treatment for ANCA-associated vasculitis in childhood DISCLOSURE I have no relevant financial relationships to disclose Katharine Moore MD Nov 14, 2012 University of Colorado School of Medicine

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A ANCA vasculitis. See Antineutrophil cytoplasmic antibody associated (ANCA) vasculitis Angiography 54 Antineutrophil cytoplasmic antibody correlation

More information

Vasculitis local: systemic

Vasculitis local: systemic Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated 2- infectious

More information

Clinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a

Clinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a Clinical Commissioning Policy: Rituximab For ANCA Vasculitis December 2012 Reference : NHSCB/ A3C/1a NHS Commissioning Board Clinical Commissioning Policy: Rituximab For The Treatment Of Anti-Neutrophil

More information

KAWASAKI DISEASE. What is Kawasaki disease? Causes

KAWASAKI DISEASE. What is Kawasaki disease? Causes What is Kawasaki disease? Kawasaki disease is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and

More information

Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis

Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis GLOMERULONEPHRITIDES Vivette D Agati Jai Radhakrishnan Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis Heavy Proteinuria Renal failure Low serum Albumin Hypertension

More information

A. Smržová. III. Interní klinika FN Olomouc nefrologická, revmatologická a endokrinologická

A. Smržová. III. Interní klinika FN Olomouc nefrologická, revmatologická a endokrinologická A. Smržová III. Interní klinika FN Olomouc nefrologická, revmatologická a endokrinologická Systemic vasculitis destructive inflamatory of the walls of blood vessels. Pathologist Inflammatory destruction

More information

Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis

Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis E.S. Park, S.S. Ahn, S.M. Jung, J.J. Song, Y.-B. Park, S.-W. Lee Division of Rheumatology, Department of Internal

More information

Protocol Version 2.0 Synopsis

Protocol Version 2.0 Synopsis Protocol Version 2.0 Synopsis Title Short Title Plasma exchange and glucocorticoid dosing in anti-neutrophil cytoplasm antibody associated vasculitis: a randomized controlled trial. PEXIVAS PEXIVAS Clinical

More information

anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid

anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid Online publication June 24, 2009 ANCA JMAAV 1 2 ANCA JMAAV MPO-ANCA 18 17 50 J Jpn Coll Angiol, 2009, 49: 53 61 anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide,

More information

Atlas of the Vasculitic Syndromes

Atlas of the Vasculitic Syndromes CHAPTER e40 Atlas of the Vasculitic Syndromes Carol A. Langford Anthony S. Fauci Diagnosis of the vasculitic syndromes is usually based upon characteristic histologic or arteriographic findings in a patient

More information

Vasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura)

Vasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura) Vasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura) J. Charles Jennette Ronald J. Falk The kidneys are affected by a variety of systemic vasculitides

More information

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable Alport Syndrome and Type IV collagenopathies APRT Deficiency Alport Syndrome definite or probable Alport carrier definite or probable Thin basement membrane nephropathy APRT Deficiency confirmed Abolished

More information

Vasculitis of the peripheral nervous system

Vasculitis of the peripheral nervous system 4 rd Congress of the European Academy of Neurology Lisbon, Portugal, June 16-19, 2018 Teaching Course 5 Acute emergencies in neuromuscular disease - Level 2 Vasculitis of the peripheral nervous system

More information

Arthritis & Rheumatism DOI /art.00000

Arthritis & Rheumatism DOI /art.00000 Special DOI 10.1002/art.00000 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross

More information

Vasculitis local: systemic

Vasculitis local: systemic Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated inflammation

More information

Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis

Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations

More information

EULAR/ERA-EDTA recommendations for the management of ANCAassociated

EULAR/ERA-EDTA recommendations for the management of ANCAassociated EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis Dr. Meharunnisha Syed III year DNB Resident (General Medicine) Narayana Health-MSH Fifteen recommendations were developed,

More information

Update and Review on Vasculitis. Ramona Raya, MD ACP Internal Medicine Congress August 7, 2015

Update and Review on Vasculitis. Ramona Raya, MD ACP Internal Medicine Congress August 7, 2015 Update and Review on Vasculitis Ramona Raya, MD ACP Internal Medicine Congress August 7, 2015 Outline Classification and nomenclature updates Small vessel vasculitis Pathophysiology Diagnosis Management/therapeutic

More information

Nierenbeteiligung bei Systemerkrankungen

Nierenbeteiligung bei Systemerkrankungen Nierenbeteiligung bei Systemerkrankungen ÖGN 2018 Irmgard Neumann www.vasculi*s.at Avacopan (CCX168) Small molecule, orally administered Highly selecgve C5aR inhibitor Prevented MPO- ANCA mediated GlomerulonephriGs

More information

TAKAYASU S ARTERITIS. Second-stage symptoms include:

TAKAYASU S ARTERITIS. Second-stage symptoms include: What is Takayasu s arteritis (TAK)? Takayasu s arteritis (TAK) is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage

More information

FAQ Identifying and enrolling participants

FAQ Identifying and enrolling participants FAQ Identifying and enrolling participants WHO IS ELIGIBLE - CASES? Patients with a new diagnosis of primary systemic vasculitis Patients suitable as cases are over 18 years with a new presentation or

More information

End-stage renal disease in ANCA-associated vasculitis

End-stage renal disease in ANCA-associated vasculitis Nephrol Dial Transplant (2017) 32: 248 253 doi: 10.1093/ndt/gfw046 Advance Access publication 6 April 2016 End-stage renal disease in ANCA-associated vasculitis Sergey Moiseev 1, Pavel Novikov 1, David

More information

Case Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013

Case Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013 Published online: January 27, 2013 1664 5510/13/0031 0016$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),

More information

Renal transplantation

Renal transplantation NEPHROLOGY 2008; 13, S37 S43 doi:10.1111/j.1440-1797.2008.00996.x Renal transplantation Date written: November 2006 Final submission: July 2007 Author: Nigel Toussaint GUIDELINES No recommendations possible

More information

The role of pathology in the diagnosis of systemic vasculitis

The role of pathology in the diagnosis of systemic vasculitis Clinical and Experimental Rheumatology 2007; 25: S52-S56 The role of pathology in the diagnosis of systemic vasculitis J.C. Jennette 1, R.J. Falk 2 1 Brinkhous Distinguished Professor and Chair of Pathology

More information

Case Presentation VASCULITIS. Case Presentation. Case Presentation. Vasculitis

Case Presentation VASCULITIS. Case Presentation. Case Presentation. Vasculitis Case Presentation VASCULITIS The patient is a 24 year old woman who presented to the emergency room with left-sided weakness. She was confused and complained of a severe headache. She was noted to have

More information

4. KIDNEYS AND AUTOIMMUNE DISEASE

4. KIDNEYS AND AUTOIMMUNE DISEASE How to Cite this article: Kidneys and Autoimmune Disease - ejifcc 20/01 2009 http://www.ifcc.org 4. KIDNEYS AND AUTOIMMUNE DISEASE Maksimiljan Gorenjak 4.1 Autoimmune diseases The human immune system limits

More information

Wegener s Granulomatosis JUN-KI PARK

Wegener s Granulomatosis JUN-KI PARK Wegener s Granulomatosis JUN-KI PARK Definition History Epidemiology Clinical symptoms Pathophysiology Treatment Wegener granulomatosis (WG) is a complex, immunemediated disorder, which along with microscopic

More information

Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases

Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases Kidney International, Vol. 65 (2004), pp. 2145 2152 Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases MARK HAAS and JOSEPH A. EUSTACE Department of Pathology

More information

Glomerular diseases mostly presenting with Nephritic syndrome

Glomerular diseases mostly presenting with Nephritic syndrome Glomerular diseases mostly presenting with Nephritic syndrome 1 The Nephritic Syndrome Pathogenesis: proliferation of the cells in glomeruli & leukocytic infiltrate Injured capillary walls escape of RBCs

More information

VASCULITIS. Case Presentation. Case Presentation

VASCULITIS. Case Presentation. Case Presentation VASCULITIS Case Presentation The patient is a 24 year old woman who presented to the emergency room with left-sided weakness. She was confused and complained of a severe headache. She was noted to have

More information

The systemic vasculitides were traditionally classified. Treatment of ANCA-associated Systemic Vasculitis. H. Michael Belmont, M.D.

The systemic vasculitides were traditionally classified. Treatment of ANCA-associated Systemic Vasculitis. H. Michael Belmont, M.D. 60 Treatment of ANCA-associated Systemic Vasculitis H. Michael Belmont, M.D. Abstract The antineutrophil cytoplasmic antibodies (ANCA)-associated small vessel vasculitides include Wegener s granulomatosis,

More information

TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE. Loïc Guillevin. Hôpital Cochin, Université Paris Descartes. DU MALADIES SYSTEMIQUES, 7 March 2014

TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE. Loïc Guillevin. Hôpital Cochin, Université Paris Descartes. DU MALADIES SYSTEMIQUES, 7 March 2014 TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE Loïc Guillevin Hôpital Cochin, Université Paris Descartes DU MALADIES SYSTEMIQUES, 7 March 2014 1 Disclosure of interest regarding this presentation Former

More information

ANCA-associated glomerulonephritis in the very elderly

ANCA-associated glomerulonephritis in the very elderly http://www.kidney-international.org & 2011 International Society of Nephrology original article see commentary on page 699 ANCA-associated glomerulonephritis in the very elderly Andrew S. Bomback 1, Gerald

More information

TITLE: Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness

TITLE: Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness TITLE: Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical and Cost-effectiveness DATE: 28 January 2015 CONTEXT AND POLICY ISSUES Granulomatosis with polyangiitis

More information

C1q nephropathy the Diverse Disease

C1q nephropathy the Diverse Disease C1q nephropathy the Diverse Disease Danica Galešić Ljubanović School of Medicine, University of Zagreb Dubrava University Hospital Zagreb, Croatia Definition Dominant or codominant ( 2+), mesangial staining

More information

EDITORIAL. Issue Seventeen, October Editorial Team. Issue Seventeen. Info link

EDITORIAL. Issue Seventeen, October Editorial Team. Issue Seventeen. Info link EDITORIAL, October 2004 Welcome to the Spring 2004 Edition of InfoLink. The feature article in this edition has been written by Dr Rodger Laurent, Head of Department, PaLMS Rheumatology Laboratory. The

More information

Clinical characteristics and outcome of vasculitides

Clinical characteristics and outcome of vasculitides GENERAL SECTION ORIGINAL ARTICLE Clinical characteristics and outcome of vasculitides Buddhi Prasad Paudyal, 1 Madhu Gyawalee 2 ISSN: 2091-2749 (Print) 2091-2757 (Online) Correspondence Dr. Buddhi Prasad

More information

EudraCT number: Page 8 of 42

EudraCT number: Page 8 of 42 EudraCT number: 2012-001102-14 Page 8 of 42 5 Trial Synopsis Title Sponsor name North American Sponsor Disease Under Investigation An international, open label, randomised, controlled trial comparing rituximab

More information

Vasculitis Prof. Dr. med. Katharina Glatz Pathologie

Vasculitis Prof. Dr. med. Katharina Glatz Pathologie Vasculitis 08-21-2018 Prof. Dr. med. Katharina Glatz Pathologie Agenda Anatomy and histology Vasculitis: Chapel Hill Classification Examples Giant cell arteritis Single organ vasculitis Artery or Vein?

More information

Jones slide di 23

Jones slide di 23 1 di 23 The patient with ANCA- associated vasculitis and pulmonary haemorrhage Rachel B Jones, Cambridge, UK Chairs:Hans-Joachim Anders, Munich, Germany Vladimir Tesar, Prague, Czech Republic Prof. Rachel

More information

Update on nomenclature and classification of vasculitis

Update on nomenclature and classification of vasculitis Update on nomenclature and classification of vasculitis Mohammadreza Shakibi M.D. Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward Adolph Kussmaul (1822 1902) First Modern

More information

Lupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia

Lupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus

More information

Vascularites associées aux ANCA Traitement par le RITUXIMAB

Vascularites associées aux ANCA Traitement par le RITUXIMAB Vascularites associées aux ANCA Traitement par le RITUXIMAB Philippe Vanhille Néphrologie Médecine Interne Hôpital de Valenciennes Aix- en- Provence 2013 Cyclophosphamide therapy of severe systemic necrotizing

More information

Antineutrophil cytoplasm antibody associated vasculitis: recent developments

Antineutrophil cytoplasm antibody associated vasculitis: recent developments mini review http://www.kidney-international.org & 2013 International Society of Nephrology Antineutrophil cytoplasm antibody associated vasculitis: recent developments Shunsuke Furuta 1 and David R.W.

More information

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable Alport Syndrome and Type IV collagenopathies APRT Deficiency Alport Syndrome definite or probable Alport carrier definite or probable Thin basement membrane nephropathy APRT Deficiency confirmed Abolished

More information

Evidence-based therapy for the ANCAassociated vasculitides: what do the trials. show so far? Clinical Trial Outcomes

Evidence-based therapy for the ANCAassociated vasculitides: what do the trials. show so far? Clinical Trial Outcomes associo far? Evidence-based therapy for the ANCAassociated vasculitides: what do the trials show so far? Anti-neutrophil cytoplasm antibody-associated vasculitides are rare multisystem inflammatory diseases

More information

Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis

Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis Clinical Kidney Journal, 2017, vol. 10, no. 4, 470 474 doi: 10.1093/ckj/sfx014 Advance Access Publication Date: 12 April 2017 Original Article ORIGINAL ARTICLE Immunoglobulin levels and infection risk

More information

Lupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017

Lupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers

More information

Avacopan in addition to standard of care for ANCA-associated vasculitis

Avacopan in addition to standard of care for ANCA-associated vasculitis EVIDENCE BRIEFING DECEMBER 2018 Avacopan in addition to standard of care for ANCA-associated vasculitis NIHRIO ID 24160 NICE ID 10023 Developer/Company ChemoCentryx and Vifor Pharma UK Ltd UKPS ID N/A

More information

EudraCT number: Page 9 of 46

EudraCT number: Page 9 of 46 EudraCT number: 2012-001102-14 Page 9 of 46 5 Trial Synopsis Title Sponsor name North American Sponsor Japan Sponsor Ireland Sponsor Disease Under Investigation An international, open label, randomised,

More information

29th Annual Meeting of the Glomerular Disease Collaborative Network

29th Annual Meeting of the Glomerular Disease Collaborative Network 29th Annual Meeting of the Glomerular Disease Collaborative Network Updates on the Pathogenesis IgA Nephropathy and IgA Vasculitis (HSP) J. Charles Jennette, M.D. Brinkhous Distinguished Professor and

More information

Clinical Case Conference Tuesday August 25, 2015 Dana Assis, MD

Clinical Case Conference Tuesday August 25, 2015 Dana Assis, MD Clinical Case Conference Tuesday August 25, 2015 Dana Assis, MD CC: LE swelling and pain for three weeks HPI: 71F hx HTN, DM (A1c 9.6), HFrEF (45%), asthma, OA, cryptogenic cirrhosis p/w bilateral lower

More information

The European and French networks. Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France

The European and French networks. Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France The European and French networks Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France French Vasculitis Study Group December 1980: L. Guillevin no research,

More information

Diagnostic Tests in Rheumatic Disease: What s Old, What s New & What s Useful? COPYRIGHT

Diagnostic Tests in Rheumatic Disease: What s Old, What s New & What s Useful? COPYRIGHT Diagnostic Tests in Rheumatic Disease: What s Old, What s New & What s Useful? Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center Boston, MA Diagnostic Tests in Rheumatic Disease: What's Old,

More information

Repeat protocol renal biopsy in ANCA-associated renal vasculitis

Repeat protocol renal biopsy in ANCA-associated renal vasculitis NDT Advance Access published February 26, 2014 Nephrol Dial Transplant (2014) 0: 1 5 doi: 10.1093/ndt/gfu042 Original Article Repeat protocol renal biopsy in ANCA-associated renal vasculitis Zdenka Hruskova

More information

MICROSCOPIC HEMATURIA AND DIFFUSE NECROTIZING GLOMERULONEPHRITIS

MICROSCOPIC HEMATURIA AND DIFFUSE NECROTIZING GLOMERULONEPHRITIS MICROSCOPIC HEMATURIA AND DIFFUSE NECROTIZING GLOMERULONEPHRITIS Hatim Q. AlMaghrabi, MD, FRCPC Consultant at King Abdulaziz Medical City (NGHA) Jeddah Case Presentation 70 years old female Known hypertensive

More information

Autoimmunity. Autoimmune Disease

Autoimmunity. Autoimmune Disease Autoimmunity Reactivity to self antigens: T cells B cells Autoimmune Disease Autoreactivity: Leading to tissue damage or dysfunction Occurring in the absence of ongoing infection 1 SLE Pathogenesis Immune

More information

Autoimmune Disease. Autoimmunity. Epidemiology. ACR Criteria for Diagnosis. Signs and Symptoms. Autoreactivity: Reactivity to self antigens:

Autoimmune Disease. Autoimmunity. Epidemiology. ACR Criteria for Diagnosis. Signs and Symptoms. Autoreactivity: Reactivity to self antigens: Autoimmunity Reactivity to self antigens: Autoreactivity: Autoimmune Disease T cells B cells Leading to tissue damage or dysfunction Occurring in the absence of ongoing infection Epidemiology SLE Pathogenesis

More information